Skip to main navigation

For Patients

|

For Physicians

Header Links

Solutions
Investors
Meet the Team
News
Careers
Contact Us
For Patients
For Physicians

News Releases

Events and Presentations

Press Coverage
News Releases
Investor Calendar

Keyword Search

Year

11/15/23

Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference

11/13/23

NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements

11/09/23

Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage

11/07/23

Neuronetics Reports Third Quarter 2023 Financial and Operating Results

11/06/23

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10/24/23

Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call

10/16/23

Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes

10/03/23

Neuronetics Draws Down Remaining $22.5 Million Available Under Credit Facility

09/12/23

In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression

08/21/23

NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards

08/14/23

Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform

08/08/23

Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results

08/04/23

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07/25/23

Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call

07/19/23

Neuronetics Announces Expanded TMS Therapy Access Through Aetna® Health Plans

07/17/23

NeuroStar Achieves Milestone Regulatory Clearance in South Korea

07/11/23

NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player

06/12/23

Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy

05/26/23

Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan

05/24/23

Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference

05/23/23

New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction

05/15/23

Neuronetics Wins 2023 Bell Seal for Workplace Mental Health

05/09/23

Neuronetics to Present at the JMP Securities Life Sciences Conference

05/09/23

Neuronetics Reports Record First Quarter 2023 Financial and Operating Results

05/08/23

Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR

05/05/23

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05/03/23

Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting

05/02/23

NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month

05/01/23

Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer

04/28/23

Neuronetics Announces Expanded TMS Access through United HealthCare

04/25/23

Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call

04/13/23

Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy

04/06/23

NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities

04/04/23

Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note

03/16/23

NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA

03/07/23

Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results

03/02/23

Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives

02/27/23

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02/23/23

Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform

02/22/23

Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call

02/21/23

Neuronetics Sponsors the 5th International Brain Stimulation Conference

02/16/23

Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer

02/10/23

Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners

01/19/23

Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership

01/18/23

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01/17/23

Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health

01/10/23

Neuronetics Settles Litigation Against BrainsWay

01/09/23

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results

Shareholder Tools

View printer-friendly version
RSS Feeds
E-mail Alerts
View contacts

*Free consultations are determined by providers and may not be guaranteed.

**Outcomes Registry data was published by Sackeim HA, et al. J Affective Disorders, 2020, 277(12):65-74. The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score <=3 and “complete remission” was defined as a CGI-S score <=2 at the end of treatment.

***Patients received more than one course of treatment and were treated with standard of care. Standard of care also included medications. CGI-S represents the scale used to define response and remission.

Indication

The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients’ results may vary.

Important Safety Information

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).

NeuroStar Advanced Therapy should not be used with patients who have non-removable conductive metal in or near the head. NeuroStar Advanced Therapy has not been studied in patients who have not received prior antidepressant treatment.

Safety and Prescribing Information »

Social Links

Our Commitment

Neuronetics is committed to compliance with state and federal laws regarding interaction with healthcare providers.

Commitment to Compliance »

To find out more about NeuroStar^® Advanced Therapy or where treatment is available near you, please provide your contact information and a Neuronetics customer service representative will contact you. The information you provide to us is subject to the Neuronetics Privacy Policy.

General Contact Information »

Customer Service Center: 877-600-7555

Copyright @ 2023 Neuronetics Inc. All Rights Reserved.
Website and materials within are for U.S. use only.